Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide

European Respiratory Journal

Volumn 30, Issue 1, 2007, Pages 26-30

  Tiev, K P ^a   Cabane, J ^a   Aubourg, F ^b   Kettaneh, A ^a   Ziani, M ^a   Mouthon, L ^b   Duong Quy, S ^b   Fajac, I ^b   Guillevin, L ^b   Dinh Xuan, Anh Tuan ^b  

^a SORBONNE UNIVERSITÉ   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Exhaled nitric oxide; Interstitial lung disease; Nitric oxide; Systemic sclerosis

Indexed keywords

BIOCHEMICAL MARKER; CARBON MONOXIDE; CORTICOSTEROID; NITRIC OXIDE;

ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; EXPIRED AIR; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; LUNG ALVEOLUS; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; TISSUE LEVEL; TOTAL LUNG CAPACITY;

AGED; CARBON MONOXIDE; ECHOCARDIOGRAPHY; FEMALE; FIBROSIS; HUMANS; LUNG DISEASES; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; NITRIC OXIDE; PROSPECTIVE STUDIES; PULMONARY ALVEOLI; SCLERODERMA, SYSTEMIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34447556844     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00129806     Document Type: Article

References (21)

1. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-2444.
2. Harrison NK, Myers AR, Corrin B, et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991; 144: 706-713.
3. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581-1586.
4. Rémy-Jardin M, Rémy J, Wallaert B, Bataille D, Hatron PY. Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage. Radiology 1993; 188: 499-506.
5. Behr J, Vogelmeier C, Beinert T, et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996; 154: 400-406.
6. Tsoukias NM, George SC. A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol 1998; 85: 653-666.
7. George SC, Högman M, Permutt S, Silkoff PE. Modeling pulmonary nitric oxide exchange. J Appl Physiol 2004; 96: 831-839.
8. Girgis RE, Gugnani MK, Abrams J, Mayes MD. Partitioning of alveolar and conducting airway nitric oxide in scleroderma lung disease. Am J Respir Crit Care Med 2002; 165: 1587-1591.
9. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-590.
10. Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997; 169: 977-983.
11. Standardization of spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 1107-1136.
12. American Thoracic Society, European Respiratory Society. ATS/ERS Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005; 171: 912-930.
13. Fajac I, Kahan A, Menkès CJ, Dessanges JF, Dall'Ava-Santucci J, Dinh-Xuan AT. Increased nitric oxide in exhaled air in patients with systemic sclerosis. Clin Exp Rheumatol 1998; 16: 547-552.
14. Moodley YP, Lalloo UG. Exhaled nitric oxide is elevated in patients with progressive systemic sclerosis without interstitial lung disease. Chest 2001; 119: 1449-1454.
15. Kharitonov SA, Cailes JB, Black CM, du Bois RM, Barnes PJ. Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 1997; 52: 1051-1055.
16. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-1665.
17. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003; 22: 358-363.
18. Dinh-Xuan AT. Endothelial modulation of pulmonary vascular tone. Eur Respir J 1992; 5: 757-762.
19. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214-221.
20. Griscavage JM, Hobbs AJ, Ignarro LJ. Negative modulation of nitric oxide synthase by nitric oxide and nitroso compounds. Adv Pharmacol 1995; 34: 215-234.
21. Clements PJ, Goldin JG, Kleerup EC, et al. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum 2004; 50: 1909-1917.